Both in Pharmaceuticals
DiaMedica Therapeutics vs PUMA BIOTECHNOLOGY
Over the past year DMAC returned +44.6% and PBYI returned +102.3%; their daily moves had a correlation of 0.19.
DMAC +44.6% PBYI +102.3%Growth of $1, one year, split-adjusted
| Metric | DMAC | PBYI |
|---|---|---|
| Price | $9.82 | $10.62 |
| Market cap | $529.6M | $548.2M |
| Today | +13.00% | −2.75% |
| 1 month | +19.8% | +8.6% |
| 6 months | +64.8% | +42.0% |
| Year to date | +23.4% | +78.5% |
| 1 year | +42.7% | +101.5% |
| Revenue growth (YoY) | — | +7.8% |
| Gross margin | — | 77.9% |
| Net margin | — | 14.5% |
| P/E (TTM) | — | 20.5× |
| Price / sales | — | 2.4× |
| Net cash | $43.5M | $93.9M |
| Dividend yield | — | — |
| Volatility (60d) | 52.3% | 43.7% |
| Short % of float | 21.5% | 11.6% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).